LivaNova PLC $LIVN Shares Sold by Harbor Capital Advisors Inc.

Harbor Capital Advisors Inc. cut its stake in LivaNova PLC (NASDAQ:LIVN) by 72.3% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 28,294 shares of the company’s stock after selling 73,871 shares during the period. Harbor Capital Advisors Inc. owned approximately 0.05% of LivaNova worth $1,482,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. GAMMA Investing LLC boosted its position in LivaNova by 90.8% during the third quarter. GAMMA Investing LLC now owns 1,202 shares of the company’s stock worth $63,000 after purchasing an additional 572 shares in the last quarter. State of Wyoming purchased a new position in shares of LivaNova during the second quarter valued at approximately $31,000. Nomura Holdings Inc. acquired a new stake in LivaNova during the second quarter worth approximately $3,918,000. Headlands Technologies LLC grew its stake in LivaNova by 270.8% in the 2nd quarter. Headlands Technologies LLC now owns 3,456 shares of the company’s stock worth $156,000 after acquiring an additional 2,524 shares during the period. Finally, Captrust Financial Advisors acquired a new stake in shares of LivaNova in the second quarter worth approximately $218,000. Hedge funds and other institutional investors own 97.64% of the company’s stock.

LivaNova Price Performance

Shares of NASDAQ LIVN opened at $62.87 on Friday. LivaNova PLC has a 1-year low of $32.48 and a 1-year high of $65.57. The firm has a market capitalization of $3.43 billion, a PE ratio of -15.72 and a beta of 1.02. The company has a debt-to-equity ratio of 0.30, a current ratio of 1.33 and a quick ratio of 1.12. The business’s fifty day moving average price is $58.30 and its two-hundred day moving average price is $52.83.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on LIVN shares. Mizuho boosted their price objective on shares of LivaNova from $70.00 to $72.00 and gave the company an “outperform” rating in a research note on Wednesday, December 17th. Robert W. Baird set a $75.00 price target on LivaNova in a research note on Tuesday, December 16th. Needham & Company LLC reiterated a “buy” rating and issued a $64.00 price target on shares of LivaNova in a report on Wednesday, September 3rd. Weiss Ratings reaffirmed a “sell (d+)” rating on shares of LivaNova in a research report on Monday. Finally, Wall Street Zen upgraded LivaNova from a “buy” rating to a “strong-buy” rating in a research note on Saturday, December 20th. Six equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $65.63.

LivaNova Profile

LivaNova plc is a global medical technology company that develops and manufactures products and therapies for the cardiac surgery and neuromodulation markets. Headquartered in London, United Kingdom, and Houston, Texas, LivaNova serves hospitals, clinics and healthcare providers in more than 100 countries. The company’s primary focus lies in advancing patient care through innovations in heart–lung bypass, cardiac preservation, circulatory support and neurostimulation therapies.

The Cardiac Surgery business unit offers a comprehensive portfolio of products used in cardiopulmonary bypass procedures, including oxygenators, heart–lung machines, arterial filters, cannulae and sutureless heart valves.